IncobotulinumtoxinA for Aesthetic Treatments: Review and Recommendations From Latin America.
Journal
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
ISSN: 1524-4725
Titre abrégé: Dermatol Surg
Pays: United States
ID NLM: 9504371
Informations de publication
Date de publication:
01 Sep 2024
01 Sep 2024
Historique:
medline:
29
8
2024
pubmed:
29
8
2024
entrez:
28
8
2024
Statut:
ppublish
Résumé
As new aesthetic treatment techniques are developed, the understanding of botulinum toxin type A safety and treatment outcomes continues to evolve. This article was developed to provide a comprehensive up-to-date reference for clinicians using incobotulinumtoxinA (INCO; Xeomin/Bocouture, Merz Pharmaceuticals GmbH, Frankfurt, Germany) for aesthetic treatments. A Latin American panel of 11 physicians was assembled to discuss and develop recommendations on the use of INCO for aesthetic treatment based on the literature review and their private medical practice. The panel found that INCO is a highly purified botulinum toxin, without other clostridial proteins (hemagglutinins and nonhemagglutinins). IncobotulinumtoxinA has proven its efficacy and duration over time, maintaining response after multiple treatment cycles. This recommendation provides up-to-date information on the use of INCO for aesthetic treatment, focusing on the differential properties of this product regarding its purity, performance, customization, and patient satisfaction.
Sections du résumé
BACKGROUND
BACKGROUND
As new aesthetic treatment techniques are developed, the understanding of botulinum toxin type A safety and treatment outcomes continues to evolve.
OBJECTIVE
OBJECTIVE
This article was developed to provide a comprehensive up-to-date reference for clinicians using incobotulinumtoxinA (INCO; Xeomin/Bocouture, Merz Pharmaceuticals GmbH, Frankfurt, Germany) for aesthetic treatments.
PATIENTS AND METHODS/MATERIALS
UNASSIGNED
A Latin American panel of 11 physicians was assembled to discuss and develop recommendations on the use of INCO for aesthetic treatment based on the literature review and their private medical practice.
RESULTS
RESULTS
The panel found that INCO is a highly purified botulinum toxin, without other clostridial proteins (hemagglutinins and nonhemagglutinins). IncobotulinumtoxinA has proven its efficacy and duration over time, maintaining response after multiple treatment cycles.
CONCLUSION
CONCLUSIONS
This recommendation provides up-to-date information on the use of INCO for aesthetic treatment, focusing on the differential properties of this product regarding its purity, performance, customization, and patient satisfaction.
Identifiants
pubmed: 39196830
doi: 10.1097/DSS.0000000000004343
pii: 00042728-202409001-00007
doi:
Substances chimiques
Botulinum Toxins, Type A
EC 3.4.24.69
incobotulinumtoxinA
EC 3.4.24.69
Neuromuscular Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
S24-S34Informations de copyright
Copyright © 2024 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.
Références
Frevert J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D 2015;15:1–9.
Park JY, Sunga O, Wanitphakdeedecha R, Frevert J. Neurotoxin impurities: a review of threats to efficacy. Plast Reconstr Surg Glob Open 2020;8:e2627.
Frevert J. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®. Drugs R D 2010;10:67–73.
Yutskovskaya Y, Gubanova E, Khrustaleva I, Atamanov V, et al. IncobotulinumtoxinA in aesthetics: Russian multidisciplinary expert consensus recommendations. Clin Cosmet Investig Dermatol 2015;8:297–306.
Sundaram H, Huang PH, Hsu NJ, Huh CH, et al. Aesthetic applications of botulinum toxin A in Asians: an international, multidisciplinary, Pan-Asian consensus. Plast Reconstr Surg Glob Open 2016;4:e872.
Sundaram H, Signorini M, Liew S, Trindade de Almeida AR, et al. Global aesthetics consensus: botulinum toxin type A--evidence-based review, emerging concepts, and consensus recommendations for aesthetic use, including updates on complications. Plast Reconstr Surg 2016;137:518e–29e.
Ali S, Al Bukhari F, Al Nuaimi K, Elenany H, et al. Consensus statement on the use of botulinum neurotoxin in the middle east. Clin Cosmet Investig Dermatol 2023;16:2899–909.
Kerscher M, Wanitphakdeedecha R, Trindade de Almeida A, Maas C, et al. IncobotulinumtoxinA: a highly purified and precisely manufactured botulinum neurotoxin type A. J Drugs Dermatol 2019;18:52–7.
Carr WW, Jain N, Sublett JW. Immunogenicity of botulinum toxin formulations: potential therapeutic implications. Adv Ther 2021;38:5046–64.
Ho WWS, Albrecht P, Calderon PE, Corduff N, et al. Emerging trends in botulinum neurotoxin A resistance: an international multidisciplinary review and consensus. Plast Reconstr Surg Glob Open 2022;10:e4407.
Shi S, Zhu H, Xia X, Liang Z, et al. Vaccine adjuvants: understanding the structure and mechanism of adjuvanticity. Vaccine 2019;37:3167–78.
Dressler D, Hefter H, Wohlfarth K, Baumer T. Botulinum neurotoxin: taking neutralizing antibodies seriously. Curr Neurol. 2014;8.
Dressler D. Therapeutically relevant features of botulinum toxin drugs. Toxicon 2020;175:64–8.
Curry A. Awareness of aesthetic and therapeutic crossover usage of botulinum neurotoxin type A. Toxicon 2024;237:107385–21.
Hefter H, Hartmann CJ, Kahlen U, Samadzadeh S, et al. Clinical improvement after treatment with IncobotulinumtoxinA (XEOMIN®) in patients with cervical dystonia resistant to botulinum toxin preparations containing complexing proteins. Front Neurol 2021;12:636590.
Hefter H, Ürer B, Brauns R, Rosenthal D, et al. Significant long-lasting improvement after switch to incobotulinum toxin in cervical dystonia patients with secondary treatment failure. Toxins (Basel) 2022;14:44.
Carey WD. Incorrect reconstitution of incobotulinumtoxinA leads to loss of neurotoxin. J Drugs Dermatol 2014;13:735–8.
Hefter H, Brauns R, Ürer B, Rosenthal D, et al. Effective long-term treatment with incobotulinumtoxin (Xeomin®) without neutralizing antibody induction: a monocentric, cross-sectional study. J Neurol 2020;267:1340–7.
Evidente VG, Truong D, Jankovic J, Comella CL, et al. IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. J Neurol Sci 2014;346:116–20.
Truong D. Botulinum neurotoxin and dystonia: a case for greater flexibility in treatment regimens. CNS J 2017;2:12–7.
Hefter H, Hartmann C, Kahlen U, Moll M, et al. Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinum toxin type A preparation free of complexing proteins--a single cohort 4-year follow-up study. BMJ Open 2012;2:e000646.
Carruthers A, Kane MAC, Flynn TC, Huang P, et al. The convergence of medicine and neurotoxins: a focus on botulinum toxin type A and its application in aesthetic medicine--a global, evidence-based botulinum toxin consensus education initiative: part I: botulinum toxin in clinical and cosmetic practice. Dermatol Surg 2013;39:493–509.
Polacco MA, Singleton AE, Barnes CH, Maas C, et al. A double-blind, randomized clinical trial to determine effects of increasing doses and dose-response relationship of IncobotulinumtoxinA in the treatment of glabellar rhytids. Aesthet Surg J 2021;41:NP500–511.
Thistle F. Greenhouse Gas Emissions, Botulinum Neurotoxin Packaging; 2012. [cited 2024 3/8/2024]. Avilable at: https://hospitalpharmacyeurope.com/news/editors-pick/greenhouse-gas-emissions-and-botulinum-neurotoxin-packaging/.
Lapatki BG, van Dijk JP, van de Warrenburg BPC, Zwarts MJ. Botulinum toxin has an increased effect when targeted toward the muscle's endplate zone: a high-density surface EMG guided study. Clin Neurophysiol 2011;122:1611–6.
Neubert J. Topographical Characterization of the Upper Facial Musculature Revealed by Means of High Density Surface Electromyography [dissertation]. University of Ulm; 2015.
de Sanctis Pecora C, Bussamara Pinheiro MV, Figueiredo V, Guerra R. Aesthetic ONE21 technique for Injecting IncobotulinumtoxinA into the forehead: initial experience with 86 patients. J Drugs Dermatol 2021;20:31–7.
de Sanctis Pecora C, Ventura Ferreira K, Amante Miot H. ONE21 technique for an individualized assessment and treatment of upper face wrinkles in five pairs of identical twins with IncobotulinumtoxinA. J Cosmet Dermatol 2022;21:1940–7.
de Sanctis Pecora C. One21: a novel, customizable injection protocol for treatment of the forehead with IncobotulinumtoxinA. Clin Cosmet Investig Dermatol 2020;13:127–36.
Abramo AC, Do Amaral TPA, Lessio BP, De Lima GA. Anatomy of forehead, glabellar, nasal and orbital muscles, and their correlation with distinctive patterns of skin lines on the upper third of the face: reviewing concepts. Aesthetic Plast Surg 2016;40:962–71.
Moqadam M, Frank K, Handayan C, Hakami M, et al. Understanding the shape of forehead lines. J Drugs Dermatol 2017;16:471–7.
da Cunha ALG, Vasconcelos R, Di Sessa D, Sampaio G, et al. IncobotulinumtoxinA for the treatment of glabella and forehead dynamic lines: a real-life longitudinal case series. Clin Cosmet Investig Dermatol 2023;16:697–704.
de Sanctis Pecora C, Pinheiro MVB, Ventura Ferreira K, Jacobino de Barros Nunes G, et al. The One21 technique: an individualized treatment for glabellar lines based on clinical and anatomical landmarks. Clin Cosmet Investig Dermatol 2021;14:97–105.
de Almeida AR, da Costa Marques ERM, Banegas R, Kadunc BV. Glabellar contraction patterns: a tool to optimize botulinum toxin treatment. Dermatol Surg 2012;38:1506–15.
Kane MA, Cox SE, Jones D, Lei X, et al. Heterogeneity of crow's feet line patterns in clinical trial subjects. Dermatol Surg 2015;41:447–56.
Tamura BM, Odo MY. Classification of periorbital wrinkles and treatment with botulinum toxin type A. Surg Cosmet Dermatol 2011;3:129–34.
Bae JH, Choi DY, Lee JG, Seo KK, et al. The risorius muscle: anatomic considerations with reference to botulinum neurotoxin injection for masseteric hypertrophy. Dermatol Surg 2014;40:1334–9.
Benedetto AV. Asymmetrical smiles corrected by botulinum toxin serotype A. Dermatol Surg 2007;33:S32–6.
Boggio RF. Dynamic model of applied facial anatomy with emphasis on teaching of botulinum toxin A. Plast Reconstr Surg Glob Open 2017;5:e1525.
Trevidic P, Sykes J, Criollo-Lamilla G. Anatomy of the lower face and botulinum toxin injections. Plast Reconstr Surg 2015;136:84S–91S.
Wu DC, Fabi SG, Goldman MP. Neurotoxins: current concepts in cosmetic use on the face and neck--lower face. Plast Reconstr Surg 2015;136:76S–79S.
Landau M, Nestor MS, de Almeida AT, Al-Niaimi F. Botulinum toxin complications in registered and off-label aesthetic indications. J Cosmet Dermatol 2020;19:2484–90.
de Maio M, Wu WTL, Goodman GJ, Monheit G, et al. Facial assessment and injection guide for botulinum toxin and injectable hyaluronic acid fillers: focus on the lower face. Plast Reconstr Surg 2017;140:393e–404e.
Angra K, Boen M, Alhaddad M, Fabi SG. Functional and aesthetic interplay between the platysma and masseter muscles. Dermatol Surg 2020;46:719–20.
de Almeida ART, Romiti A, Carruthers JDA. The facial platysma and its underappreciated role in lower face dynamics and contour. Dermatol Surg 2017;43:1042–9.
Park JY, Cho SI, Hur K, Lee DH. Intradermal microdroplet injection of diluted Incobotulinumtoxin-A for sebum control, face lifting, and pore size improvement. J Drugs Dermatol 2021;20:49–54.
Vachiramon V, Kositkuljorn C, Leerunyakul K, Rattananukrom T, et al. A study of botulinum toxin A for ultraviolet-induced hyperpigmentation: a randomized controlled trial. Dermatol Surg 2021;47:e174–8.
Oh SH, Lee Y, Seo YJ, Lee JH, et al. The potential effect of botulinum toxin type A on human dermal fibroblasts: an in vitro study. Dermatol Surg 2012;38:1689–94.
Dayan SH, Pritzker RN, Arkins JP. A new treatment regimen for rosacea: onabotulinumtoxinA. J Drugs Dermatol 2012;11:e76–9.
Zhang L, Wang W, Wang S. Effect of vaccine administration modality on immunogenicity and efficacy. Expert Rev Vaccines 2015;14:1509–23.